Lifileucel
Metastatic Renal Pelvis Urothelial Carcinoma
Roswell Park Cancer InstituteCell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Metastatic Renal Pelvis Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BB |
Pembrolizumab Fred Hutchinson Cancer Center | Phase 3 | BB |
MITOMYCIN C UroGen Pharma Ltd. | Phase 3 | B |
Relatlimab National Cancer Institute (NCI) | Phase 2/3 | B |
View all 22 →
Same molecule, other indications
Lifileucel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →